<DOC>
	<DOC>NCT02076399</DOC>
	<brief_summary>The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).</brief_summary>
	<brief_title>A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Clinical diagnosis of persistent/chronic ITP for at least 3 months. Average platelet count &lt; 30,000/ÂµL (and none &gt; 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts Clinical diagnosis of autoimmune hemolytic anemia Uncontrolled or poorly controlled hypertension History of coagulopathy including prothrombotic conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Persistent Immune Thrombocytopenic Purpura</keyword>
	<keyword>Chronic Immune Thrombocytopenic Purpura</keyword>
</DOC>